Maintenance Renal Transplantation
Conditions
Keywords
Renal transplantation, EC-MPS
Brief summary
The aim of this study is to evaluate if the addition of EC-MPS to CsA-ME allows the safe withdrawal of the concomitant corticosteroid therapy in long-term maintenance renal allograft recipients. All patients of the core study who are interested of being treated with EC-MPS will be included in an open-label extension study to collect further information on the long-term safety, tolerability and efficacy of this drug.
Interventions
Sponsors
Novartis
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
1\. Male or female, 18 years of age or older. 2. Recipients of first or secondary cadaver, living related or unrelated donor kidney transplant performed at least 6 month before screening (Visit 1) 3. Patients currently receiving CsA-ME and corticosteroids (at least 5 mg of prednisone equivalents) for at least 3 months prior to Screening, with or without Mycophenolate mofetil or azathioprine. 4\. Serum creatinine levels \< 2.3 mg/dL (=204 µmol/L) at screening and at baseline 5. Stable kidney function, i.e. increase in serum creatinine less than 20% in the last 3 months before screening and at baseline (baseline value as compared to the value obtained at screening)
Exclusion criteria
1. Multi-organ recipients (e.g., kidney and pancreas, double kidneys) or previous transplant with any other organ different from kidney 2. Patients whit a second transplant who rejected the first one for immunological reasons or because of the relapse of the autoimmune disease which leaded to the end-stage renal failure 3. Histological evidence of acute rejection or treatment for acute rejection within the three months prior to Screening, or histological signs or clinical signs of chronic rejection (as significant proteinuria, i.e. \> 300 mg/24 hours. 4. Patients with maintenance steroid therapy for other diseases (i.e. autoimmune diseases, Lupus). 5. Patients with any known hypersensitivity to EC-MPS or other components of the formulation (e.g., lactose) 6. Patients with thrombocytopenia (\<75,000/mm3), with an absolute neutrophil count of \<1,500/mm3 and/or leukocytopenia (\<4,000/mm3), and/or anemia (hemoglobin \<9.0 g/dL) prior to Screening visit. 7. Patients who have received an investigational drug within two weeks prior to Screening visit. 8. Patients with a history of malignancy within the last five years, except excised squamous or basal cell carcinoma of the skin. 9. Females of childbearing potential who are planning to become pregnant, who are pregnant and/or lactating, who are unwilling to use effective means of contraception 10. Presence of clinically significant infection requiring continued therapy, severe diarrhea, active peptic ulcer disease, or uncontrolled diabetes mellitus that would interfere with the appropriate conduct of the study. 11. Any changes of immunosuppressive regimen due to graft malfunction, or any known clinically significant physical and/or laboratory changes in the 2 months prior to Screening visit. 12. Known positivity for HIV, HBsAg 13. Active viral hepatitis, as shown by liver function tests (AST or ALT) higher than twice the upper limit of normality 14. Evidence of drug and/or alcohol abuse Other inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of biopsy prove acute rejection requiring treatment within six months of the start of the study. | — |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of the changes in body-weight, blood pressure, serum lipid levels, renal function, glaciated hemoglobin, dermatological condition and quality of life six months after the start of the study | — |
| Safety and tolerability | — |
| Pharmacokinetics of MPA and MPAG in the patient subgroup that was receiving MMF (screening period) before the start of the study and two weeks after the start of the administration of EC-MPS. | — |
Outcome results
None listed